Cognition Therapeutics, Inc. (CGTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 26.14M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 1.53M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -36.60M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $26.14M | (m) | $1.53M | $-36.60M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $32.52M | (m) | $1.83M | $-42.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $37.19M | (m) | $2.09M | $-47.80M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $34.19M | (m) | $2.26M | $-44.85M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $41.81M | (m) | $2.64M | $-52.94M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $41.91M | (m) | $3.16M | $-53.64M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $41.68M | (m) | $3.75M | $-53.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $45.12M | (m) | $4.29M | $-58.43M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $45.40M | (m) | $4.46M | $-58.71M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $42.32M | (m) | $4.34M | $-55.85M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $37.20M | (m) | $4.35M | $-50.72M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $32.04M | (m) | $4.18M | $-44.84M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $28.64M | (m) | $3.89M | $-42.72M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $29.24M | (m) | $3.76M | $-43.11M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $30.32M | (m) | $3.57M | $-43.55M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $29.46M | (m) | $7.59M | $-46.06M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $24.86M | (m) | $6.88M | $-38.66M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $20.66M | (m) | $6.09M | $-32.43M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $18.57M | (m) | $5.18M | $-28.60M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $12.89M | (m) | $475.00K | $-17.41M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |